Dark

Check out our Level2View

CING
Cingulate Inc. Common Stock
stock NASDAQ

At Close

Jul 14, 2025 3:59:30 PM EDT

4.72USD+8.506%(+0.37)187,249

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 14, 2025 8:59:30 AM EDT

4.25USD-2.299%(-0.10)157

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

06:54AM EST Cingulate Appoints Curt Medeiros And Gregg Givens To Board RTTNews

Jan 20, 2022

10:41AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022 Benzinga

09:17AM EST Laidlaw & Co. Initiates Coverage On Cingulate with Buy Rating, Announces Price Target of $8.5 Benzinga

Jan 11, 2022

10:09AM EST Aegis Capital Initiates Coverage On Cingulate with Buy Rating, Announces Price Target of $9 Benzinga

09:53AM EST Watching Cingulate; AEGIS Capital Earlier Issued Buy Rating, $9 Price Target Benzinga

Dec 12, 2021

04:56PM EST The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More Benzinga

Dec 10, 2021

11:00AM EST Cingulate Inc. Announces Closing of Initial Public Offering GlobeNewswire Inc

Dec 8, 2021

11:10AM EST Cingulate Shares Open For Trade At $5; IPO Priced $6/Share Benzinga

10:33AM EST Cingulate Shares Will Open For Quote At 11 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST; IPO Priced $6/Share Benzinga

Dec 7, 2021

09:05PM EST Cingulate Inc. Announces Pricing of $25.0 Million Initial Public GlobeNewswire Inc

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Share